X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
humans (16) 16
oncology (15) 15
cancer (12) 12
female (9) 9
male (7) 7
chemotherapy (5) 5
metastasis (5) 5
middle aged (5) 5
research (5) 5
solid tumors (5) 5
aged (4) 4
neoplasms - drug therapy (4) 4
retrospective studies (4) 4
therapy (4) 4
adult (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer therapies (3) 3
clinical trials (3) 3
disease progression (3) 3
double-blind (3) 3
immunotherapy (3) 3
molecular targeted therapy (3) 3
open-label (3) 3
phase-iii trial (3) 3
sarcoma (3) 3
toxicity (3) 3
treatment outcome (3) 3
trial (3) 3
tumors (3) 3
1st-line treatment (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antitumor-activity (2) 2
biomedicine (2) 2
cancer stem cells (2) 2
care and treatment (2) 2
cell biology (2) 2
challenges (2) 2
continuation (2) 2
criteria (2) 2
diagnosis (2) 2
drug design (2) 2
drugs (2) 2
kaplan-meier estimate (2) 2
label-retaining cell (2) 2
management (2) 2
medical prognosis (2) 2
melanoma (2) 2
metastases (2) 2
methotrexate (2) 2
multicenter (2) 2
neck (2) 2
neoplasms - therapy (2) 2
nivolumab (2) 2
patients (2) 2
pazopanib (2) 2
pharmaceutical sciences/technology (2) 2
pharmacology/toxicology (2) 2
pharmacotherapy (2) 2
platinum (2) 2
predictive value of tests (2) 2
prognostic factors (2) 2
protein kinase inhibitors - adverse effects (2) 2
q-twist (2) 2
quality of life (2) 2
quiescence (2) 2
randomized phase-ii (2) 2
rechallenge (2) 2
renal cell carcinoma (2) 2
risk factors (2) 2
safety (2) 2
sarcoma - drug therapy (2) 2
skin cancer (2) 2
studies (2) 2
survival (2) 2
targeted therapies (2) 2
trabectedin (2) 2
5-fluorouracil (1) 1
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
abridged index medicus (1) 1
accuracy (1) 1
adjuvant trastuzumab (1) 1
adrenal cortex hormones - therapeutic use (1) 1
advanced breast-cancer (1) 1
adverse events (1) 1
aged, 80 and over (1) 1
albumin (1) 1
alpha (1) 1
angiogenesis inhibitors - adverse effects (1) 1
angiogenesis inhibitors - chemistry (1) 1
angiogenesis inhibitors - pharmacology (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
antiangiogenic (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
anticancer properties (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current Opinion in Oncology, ISSN 1040-8746, 09/2019, Volume 31, Issue 5, pp. 439 - 444
PURPOSE OF REVIEWThe aim of this review is to provide an overview of the current development of immuno-oncology in the (neo)adjuvant setting. RECENT... 
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 05/2017, Volume 104, Issue 5, pp. 442 - 451
Bipolar disorders belong to the spectrum of mood disorders and represent a serious psychiatric comorbidity. Behaviors adopted by bipolar patients can foster... 
Manic episode | Mood stabilizer | Atypical antipsychotic drugs | Mood disorders | Bipolar disorders | Cancer
Journal Article
Bulletin du cancer, 05/2017, Volume 104, Issue 5, p. 442
Journal Article
by Cohen, Ezra E W and Cohen, Ezra and Soulières, Denis and Le Tourneau, Christophe and Dinis, Jose and Dinis, José and Licitra, Lisa and Ahn, Myung-Ju and Soria, Ainara and Machiels, Jean-Pascal and Mach, Nicolas and Mehra, Ranee and Burtness, Barbara Ann and Burtness, Barbara and Zhang, Pingye and Cheng, Jonathan and Swaby, Ramona F and Harrington, Kevin and Harrington, Kevin J and Acosta-Rivera, Mirelis and Adkins, Douglas R and Aghmesheh, Morteza and Airoldi, Mario and Aleknavicius, Eduardas and Al-Farhat, Yousuf and Algazi, Alain P and Almokadem, Salah and Alyasova, Anna and Bauman, Jessica R and Benasso, Marco and Berrocal, Alfonso and Bray, Victoria and Caponigro, Francesco and Castro, Ana and Cescon, Terrence P and Chan, Kelvin and Chaudhry, Arvind and Chauffert, Bruno and Csoszi, Tibor and De Boer, J.P and Delord, Jean-Pierre and Dietz, Andreas and Dupuis, Charlotte and Digue, Laurence and Erfan, Jozsef and Escobar Alvarez, Yolanda and Evans, Mererid and Fidler, Mary Jo and Forster, Martin David and Friesland, Signe and Ganti, Apar K and Geoffrois, Lionnel and Grant, Cliona and Gruenwald, Viktor and Hoffmann, Thomas and Horvai, Geza and Inciura, Arturas and Jang, Raymond and Jankowska, Petra and Jimeno, Antonio and Joseph, Mano and Juarez Ramiro, Alejandro and Karaszewska, Boguslawa and Kawecki, Andrzej and Keilholz, Ulrich and Keller, Ulrich and Kim, Sung-Bae and Kocsis, Judit and Kotecki, Nuria and Kozloff, Mark F and Lambea, Julio and Landherr, Laszlo and Lantsukhay, Yuri and Lazarev, Sergey Alexandrovich and Lee, Lip Way and Lifirenko, Igor Dmitrievich and Martincic, Danko and Matorin, Oleg Vladmirovhich and McGrath, Margaret and Misiukiewicz, Krzysztof and Morris, John C and Mufazalov, Fagim Fanisovich and Niu, Jiaxin and Pamoorthy Srinivasan, Devraj and Perez Segura, Pedro and Rauch, Daniel and Ribeiro, Maria Leonor and Rodriguez, Cristina and Rolland, Frederic and Russo, Antonio and Ruzsa, Agnes and Sanches, Frederico and Shin, Sang-Won and Shtiveland, Mikhail and Soulieres, Denis and Specenier, Pol and Szekanecz, Eva and Szota, Judit and van Herpen, Carla M.L and Velez-Cortes, Hector A and ... and Keynote-040 Investigators and KEYNOTE-040 investigators
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 156 - 167
There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour... 
CRITERIA | TRIAL | MEDICINE, GENERAL & INTERNAL | NIVOLUMAB | CANCER | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Docetaxel - adverse effects | Humans | Middle Aged | Squamous Cell Carcinoma of Head and Neck - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Cetuximab - therapeutic use | Cetuximab - adverse effects | Docetaxel - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Squamous Cell Carcinoma of Head and Neck - drug therapy | Female | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Disease Progression | Head and Neck Neoplasms - pathology | Methotrexate - adverse effects | Squamous Cell Carcinoma of Head and Neck - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cetuximab - administration & dosage | Methotrexate - administration & dosage | Aged | Methotrexate | Squamous cell carcinoma | Metastasis | Therapy | Toxicity | Perforation | Clinical trials | Oncology | Cancer therapies | Metastases | Skin cancer | Anticancer properties | Pembrolizumab | Randomization | Motivation | Platinum | Neck | Safety | Medical treatment | Fatigue | Hypothyroidism | Survival | Patients | Chemotherapy | Interactive systems | Large intestine | Head and neck cancer | Ligands | Tumors
Journal Article
Current Opinion in Oncology, ISSN 1040-8746, 09/2018, Volume 30, Issue 5, pp. 330 - 331
Journal Article
Current Opinion in Oncology, ISSN 1040-8746, 09/2019, Volume 31, Issue 5, pp. 420 - 423
PURPOSE OF REVIEWImmune checkpoint inhibitors (ICIs) are rapidly changing practice across different tumor settings. With this article, we reflect on how to... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1040 - 1040
Introduction: Signal Regulatory Protein α [SIRPα] is a polymorphic protein, strongly expressed on myeloid suppressive cells. BI 765063 (OSE172), a humanized... 
Journal Article
Current Opinion in Oncology, ISSN 1040-8746, 09/2017, Volume 29, Issue 5, pp. 400 - 404
Purpose of reviewDespite recent changes in clinical research methodology, many challenges remain in drug development methodology.Recent findingsAdvances in... 
unmet need | new drugs | solid tumors | innovative approach | network | CANCERS | ONCOLOGY | CHALLENGES | Neoplasms - genetics | Neoplasms - immunology | Humans | Drug Design | Biomedical Research | Clinical Trials as Topic - methods | Neoplasms - drug therapy | Index Medicus
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 12/2019, Volume 7, Issue 1, pp. 1 - 9
Abstract Background Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of... 
Avelumab | PD-L1 | Metastatic | Phase I | Renal cell carcinoma
Journal Article
Bulletin du cancer, 10/2015, Volume 102, Issue 10, pp. 804 - 805
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e22534 - e22534
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.